International Flavors & Fragrances Inc. (BIT:1IFF)
Italy
· Delayed Price · Currency is EUR 66.02
-1.08 (-1.61%)
At close: May 23, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 - 2020 |
| Nourish | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nourish Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Health & Biosciences | 2.22B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Health & Biosciences Growth | 5.91% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scent | 2.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scent Growth | -0.86% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharma Solutions | 1.00B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharma Solutions Growth | 6.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capex by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2018 - 2019 |
| Nourish Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nourish Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Health & Biosciences Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Health & Biosciences Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scent Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scent Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharma Solutions Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharma Solutions Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 - 2020 |
| Nourish Adjusted Operating EBITDA | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nourish Adjusted Operating EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Health & Biosciences Adjusted Operating EBITDA | 633.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Health & Biosciences Adjusted Operating EBITDA Growth | 6.39% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scent Adjusted Operating EBITDA | 505.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scent Adjusted Operating EBITDA Growth | -3.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharma Solutions Adjusted Operating EBITDA | 217.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharma Solutions Adjusted Operating EBITDA Growth | 16.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|